Affini-T is developing specific TCR-based immunotherapies for solid tumors using two complementary therapeutic modalities
Latest News
03.13.2024
Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting
Press Releases
01.07.2024
Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Press Releases
11.13.2023
Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer
Press Releases